Nirvana Life Sciences Inc. Announces the Appointment of Jakson Inwentash to the Board of Directors Psychedelics Investing
COMPASS Pathways plc to announce first quarter 2022 financial results on 10 May 2022 Psychedelics Investing
COMP360 psilocybin therapy shows potential in exploratory open-label studies for anorexia nervosa and severe treatment-resistant depression Psychedelics Investing
Vireo Health of Minnesota® and Green Goods® Launch the Green Ticket Giveaway Psychedelics Investing
Nirvana Life Sciences: Psychedelics for Opioid Addiction Recovery and Pain Management Psychedelics Investing
KCSA Psychedelics Virtual Investor Conference Presentations Now Available for On-Demand Viewing Psychedelics Investing
Awakn Life Sciences Reports Fiscal Fourth Quarter and Fiscal Year January 31, 2022, Results Psychedelics Investing
Optimi Health Opens Canada's Largest GMP-Grade Licensed Psilocybin Cultivation Facility Psychedelics Investing
